Steroid-Resistant Asthma Medication Study

Trial Objective

This study is for asthmatics who continue to have asthma symptoms despite daily treatment with medications such as inhaled corticosteroids (e.g., Flovent) or inhaled corticosteroids with long-acting beta agonists and/or long-acting muscarinic antagonists (e.g., Advair). Participants cannot be on Prednisone for six weeks before the trial begins.

The purpose of the study is to see if a new investigational medication can control inflammation, mucous production and swelling in the lungs, as well as difficulty breathing in people with steroid-resistant asthma.

Study participation involves:

  • 2 visits over 7-8 days
  • Blood draw
  • Questionnaires
  • Spirometry at no cost to you
  • Study medication at no cost to you

Enrollment

This trial is active and currently recruiting.

How to Participate

For more information, call Mary at 303.398.1443 or complete the form below

Who Can Participate

Individuals 18-65 years of age who have asthma symptoms despite daily treatment with inhaled corticosteroid or inhaled corticosteroid with long-acting beta agonists and/or long-acting muscarinic antagonists medications.


Age

18-65


Gender

Any Gender

Trial Location

National Jewish Main Campus, Denver, CO

Compensation

Provided

Trial Sponsors

AstraZenec


Estimated Time Commitment

2 visits over 7-8 days

Principal Investigators


Request More Information

*
*
*
*